Skip to main content

Navigating the Regulatory Process for Psychedelic Medicine

This program covers drug policy, FDA approval, DEA regulations, and advocacy opportunities as they relate to psychedelic-assisted therapy.


Victor Cabral, MSW, LSW, CCTP-I


$25 Includes .5 hours of APA CE and NYSED CE for Psychologists, Social Workers, and LMHCs

Course Description

Learning Objectives

At the end of this course, the participant will be able to:

  • Articulate the role of colonization in the formation of drug policy in the United States
  • Identify one way US Drug policy impacts psychedelic drug research
  • Define and delineate FDA breakthrough designation from other FDA designations
  • Identify the DEA scheduling status of psilocybin, MDMA, and ketamine
  • Identify where MDMA, psilocybin, and ketamine are in the process of approval for use in psychedelic-assisted therapy
  • Name at least one policy issue currently facing the field of psychedelic-assisted therapy
  • Identify at least 1 way to support the successful adoption of psychedelic therapies post FDA-approval
start now
information for medical professionals and about CEs

Other Upcoming Courses

Thanks for signing up for our newsletter!
please enter a valid email address.